Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 3
1975 7
1976 6
1979 2
1980 1
1981 1
1982 2
1983 1
1984 2
1985 1
1987 3
1988 5
1989 1
1990 2
1991 2
1993 3
1994 1
1995 1
1997 1
1998 2
2000 1
2001 1
2002 2
2003 1
2004 4
2005 4
2006 2
2007 4
2008 3
2009 7
2010 8
2011 5
2012 13
2013 12
2014 11
2015 20
2016 10
2017 9
2018 13
2019 3
2020 13
2021 19
2022 12
2023 9
2024 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

214 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators. Mateos MV, et al. N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12. N Engl J Med. 2018. PMID: 29231133 Free article. Clinical Trial.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Wang ML, et al. Among authors: jedrzejczak ww. N Engl J Med. 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19. N Engl J Med. 2013. PMID: 23782157 Free PMC article. Clinical Trial.
Leukaemia cutis for clinicians, a literature review.
Osmola M, Gierej B, Kłosowicz A, Waszczuk-Gajda A, Basak GW, Jędrzejczak WW, Jurczyszyn A, Ziarkiewicz-Wróblewska B. Osmola M, et al. Among authors: jedrzejczak ww. Postepy Dermatol Alergol. 2021 Jun;38(3):359-365. doi: 10.5114/ada.2021.107923. Epub 2021 Jul 26. Postepy Dermatol Alergol. 2021. PMID: 34377113 Free PMC article. Review.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Free article. Clinical Trial.
Clinical features, etiology, and survival in patients with restrictive cardiomyopathy: A single-center experience.
Szczygieł JA, Michałek P, Truszkowska G, Drozd-Sokołowska J, Wróbel A, Franaszczyk M, Gawor-Prokopczyk M, Mazurkiewicz Ł, Ziarkiewicz M, Waszczuk-Gajda A, Legatowicz-Koprowska M, Walczak E, Stawiński P, Lutyńska A, Płoski R, Jędrzejczak WW, Bilińska ZT, Grzybowski J. Szczygieł JA, et al. Among authors: jedrzejczak ww. Kardiol Pol. 2023;81(12):1227-1236. doi: 10.33963/v.kp.97879. Epub 2023 Nov 8. Kardiol Pol. 2023. PMID: 37937352 Free article.
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.
Fenaux P, Gobbi M, Kropf PL, Issa JJ, Roboz GJ, Mayer J, Krauter J, Robak T, Kantarjian H, Novak J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein J, Gercheva-Kyuchukova L, Demeter J, Griffiths E, Yee K, Döhner K, Hao Y, Keer H, Azab M, Döhner H. Fenaux P, et al. Among authors: jedrzejczak ww. Blood Adv. 2023 Sep 12;7(17):5027-5037. doi: 10.1182/bloodadvances.2023010179. Blood Adv. 2023. PMID: 37276510 Free PMC article. Clinical Trial.
[Chemotherapy of malignant melanoma].
Jedrzejczak WW. Jedrzejczak WW. Pol Arch Med Wewn. 1998 Oct;100(4):294-9. Pol Arch Med Wewn. 1998. PMID: 10335037 Polish. No abstract available.
214 results